Skip to main content
Erschienen in:

01.01.2005 | Update Onkologie

Aktuelle Optionen der taxanbasierten Chemotherapie des hormonrefraktären Prostatakarzinoms

verfasst von: Prof. Dr. A. Heidenreich, J. Wolf, K. Miller

Erschienen in: Die Onkologie | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Standardtherapie des metastasierten Prostatakarzinoms besteht in der medikamtösen oder chirurgischen Androgendeprivation, die zu einem therapeutischen Ansprechen bei ca. 90% der Patienten führt. Bis zu 90% dieser Patienten werden innerhalb der ersten 2–3 Jahre ein progredientes hormonrefraktäres Prostatakarzinom entwickeln, das uns noch immer vor eine therapeutische Herausforderung stellt. Die Indikation zur systemischen Chemotherapie wurde in den vergangenen Jahren aufgrund der suboptimalen Resultate zurückhaltend und in erster Linie in der palliativen Situation gestellt. Aufgrund aktueller Ergebnisse prospektiv-randomisierter klinischer Phase-III-Studien mit Docetaxel im Vergleich zu Mitoxantron hat sich erstmals ein Überlebensvorteil für eine systemische Chemotherapie darstellen lassen. Unter Docetaxel kommt es zu einem statistisch signifikanten Überlebensbenefit von 2,5 Monaten, einem signifikant höheren PSA-Ansprechen und einem signifikant günstigeren schmerztherapeutischen Ansprechen als unter Mitoxantron. Docetaxel stellt derzeit die Referenztherapie in der systemischen Behandlung des hormonrefraktären Prostatakarzinoms dar. Trotz dieser positiven Resultate müssen zukünftig Kombinationstherapien mit höherer Effektivität untersucht werden, um das Überleben klinisch signifikant zu verbessern. In dem vorliegenden Artikel sollen Entwicklung, Rationale und Resultate der docetaxelbasierten Chemotherapie dargelegt werden.
Literatur
1.
Zurück zum Zitat Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer Statistics, 1997. CA Cancer J Clin 46:5–27PubMed Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer Statistics, 1997. CA Cancer J Clin 46:5–27PubMed
2.
Zurück zum Zitat Wingo PA, Landis S, Ries LAG (1997) An adjustment to the 1997 estimate for new prostate cancer. CA Cancer J Clin 47:239–242PubMed Wingo PA, Landis S, Ries LAG (1997) An adjustment to the 1997 estimate for new prostate cancer. CA Cancer J Clin 47:239–242PubMed
3.
Zurück zum Zitat Scher H, Steinneck G, Kelly WK (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46:142–148PubMed Scher H, Steinneck G, Kelly WK (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46:142–148PubMed
4.
Zurück zum Zitat Vogelzang NJ, Crawford ED, Zietman A (1998) Current clinical trial design issues in hormone-refractory prostate cancer. Cancer 82:2093–2101PubMed Vogelzang NJ, Crawford ED, Zietman A (1998) Current clinical trial design issues in hormone-refractory prostate cancer. Cancer 82:2093–2101PubMed
5.
Zurück zum Zitat Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMed Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMed
6.
Zurück zum Zitat Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506–2513PubMed Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506–2513PubMed
7.
Zurück zum Zitat Eisenberger MA, Abrams JS (1988) Chemotherapy for prostatic carcinoma. Semin Urol 6:303–310PubMed Eisenberger MA, Abrams JS (1988) Chemotherapy for prostatic carcinoma. Semin Urol 6:303–310PubMed
8.
Zurück zum Zitat Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 [Suppl 3]: 1098–1111PubMed Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 [Suppl 3]: 1098–1111PubMed
9.
Zurück zum Zitat Heidenreich A, Schrader AJ (2003) The treatment of hormone refractory prostate cancer. EUA Update Series 1:40–50 Heidenreich A, Schrader AJ (2003) The treatment of hormone refractory prostate cancer. EUA Update Series 1:40–50
10.
Zurück zum Zitat Eisenberger MA, de Wit R, Berry W et al. (2004) A multicenter phase III trial of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refactory prostate cancer. Proc ASC0 23:2, # 4 Eisenberger MA, de Wit R, Berry W et al. (2004) A multicenter phase III trial of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refactory prostate cancer. Proc ASC0 23:2, # 4
11.
Zurück zum Zitat Petrylak DP, Tangen C, Hussain M et al. (2004) SWOG 99–16: randomized phase III trial of docetaxel(D)/estramustine (E) versus mitoxantrone(M)/prednisone(P) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 23:2, # 3 Petrylak DP, Tangen C, Hussain M et al. (2004) SWOG 99–16: randomized phase III trial of docetaxel(D)/estramustine (E) versus mitoxantrone(M)/prednisone(P) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 23:2, # 3
12.
Zurück zum Zitat Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467PubMed Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467PubMed
13.
Zurück zum Zitat Dawson NA (1998) Apples and oranges: Building a consensus for standardized eligibilty criteria and end points in prostate cancer clinical trials. J Clin Oncol 16:3398–3405PubMed Dawson NA (1998) Apples and oranges: Building a consensus for standardized eligibilty criteria and end points in prostate cancer clinical trials. J Clin Oncol 16:3398–3405PubMed
14.
Zurück zum Zitat George DJ, Kanthoff PW (1999) Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 26:303–309PubMed George DJ, Kanthoff PW (1999) Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 26:303–309PubMed
15.
Zurück zum Zitat De Voogt HJ, Sucuiu S, Sylvester R (1989) Univariate analysis of prognostic factors in patients with advanced prostatic carcinoma: results from two European organization for research on treatment of cancer trials. J Urol 141:883–888PubMed De Voogt HJ, Sucuiu S, Sylvester R (1989) Univariate analysis of prognostic factors in patients with advanced prostatic carcinoma: results from two European organization for research on treatment of cancer trials. J Urol 141:883–888PubMed
16.
Zurück zum Zitat Denis L (1998) European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976–1996. Urology 51 [Suppl 5A]: 50–57 Denis L (1998) European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976–1996. Urology 51 [Suppl 5A]: 50–57
17.
Zurück zum Zitat Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Aneamia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933–941PubMed Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Aneamia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933–941PubMed
18.
Zurück zum Zitat Bland LB, Tangen CM, Thompson IM et al. (2004) Prognostic value of anemia in untreated metastatic prostate cancer: a mukltivariate analysis of SWOG 8894. Proc ASCO 23:399, #4574 Bland LB, Tangen CM, Thompson IM et al. (2004) Prognostic value of anemia in untreated metastatic prostate cancer: a mukltivariate analysis of SWOG 8894. Proc ASCO 23:399, #4574
19.
Zurück zum Zitat Smith DC, Dunn RL, Strawderman MS, Pienta KJ (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835–1843PubMed Smith DC, Dunn RL, Strawderman MS, Pienta KJ (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835–1843PubMed
20.
Zurück zum Zitat Small EJ, McMillan A, Meyer M et al. (2001) Serum prostate antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer: association with progression free survival, pain end points and survival. J Clin Oncol 19:1304PubMed Small EJ, McMillan A, Meyer M et al. (2001) Serum prostate antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer: association with progression free survival, pain end points and survival. J Clin Oncol 19:1304PubMed
21.
Zurück zum Zitat Verbel DA, Heller G, Kelly WK, Scher HI (2002) Quantifying the amount of variation in survival explained by Prostate-specific antigen. Clin Cancer Res 8:2576–2579PubMed Verbel DA, Heller G, Kelly WK, Scher HI (2002) Quantifying the amount of variation in survival explained by Prostate-specific antigen. Clin Cancer Res 8:2576–2579PubMed
22.
Zurück zum Zitat Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hersey D, Gordon R, Rohner T, Drago J, Wettlaufer J, Glode L (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6:1456–1466PubMed Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hersey D, Gordon R, Rohner T, Drago J, Wettlaufer J, Glode L (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6:1456–1466PubMed
23.
Zurück zum Zitat Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a southwest oncology group report. J Clin Oncol 12:1868–1875 Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a southwest oncology group report. J Clin Oncol 12:1868–1875
24.
Zurück zum Zitat Taylor CD, Elson P, Trump DL (1993) Importance of testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11:2167–2172PubMed Taylor CD, Elson P, Trump DL (1993) Importance of testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11:2167–2172PubMed
25.
Zurück zum Zitat Crawford ED, Rosenblum M, Ziada AM, Lange PH (1999) Overview: hormone refractory prostate cancer. Urology 54 [Suppl 6A]: 1–7 Crawford ED, Rosenblum M, Ziada AM, Lange PH (1999) Overview: hormone refractory prostate cancer. Urology 54 [Suppl 6A]: 1–7
26.
Zurück zum Zitat Roth BJ, Yeap BY, Wilding G (1993) Taxol in advanced hormone-refractory prostate carcinoma: phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457–2460PubMed Roth BJ, Yeap BY, Wilding G (1993) Taxol in advanced hormone-refractory prostate carcinoma: phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457–2460PubMed
27.
Zurück zum Zitat Trovedi C, Redman B, Flaherty LE et al. (2000) Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone refractory prostate carcinoma. Cancer 89/2:431–436 Trovedi C, Redman B, Flaherty LE et al. (2000) Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone refractory prostate carcinoma. Cancer 89/2:431–436
28.
Zurück zum Zitat Kelly WK, Curley T, Slovin S et al. (2001) Paclitaxel, estramustin phosphate and carboplatin in patients with advanced prostate cancer. J Clin ONcol 19:44–53PubMed Kelly WK, Curley T, Slovin S et al. (2001) Paclitaxel, estramustin phosphate and carboplatin in patients with advanced prostate cancer. J Clin ONcol 19:44–53PubMed
29.
Zurück zum Zitat Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664–1671PubMed Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664–1671PubMed
30.
Zurück zum Zitat Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shi H (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168:2444–2450PubMed Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shi H (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168:2444–2450PubMed
31.
Zurück zum Zitat Schultz M, Wei J, Picus J et al. (1999) A phase II Trial of docetaxcel in Patients with homone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol 18:355a Schultz M, Wei J, Picus J et al. (1999) A phase II Trial of docetaxcel in Patients with homone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol 18:355a
32.
Zurück zum Zitat Friedland D, Cohen J, Miller R et al. A phase II trial of Taxotere® in hormone refractory prostate cancer: Correlation of antitumor activity to phosphorylation of bcl-2. [abstract] Proc Am Soc Clin Oncol 35:1237, 1999 Friedland D, Cohen J, Miller R et al. A phase II trial of Taxotere® in hormone refractory prostate cancer: Correlation of antitumor activity to phosphorylation of bcl-2. [abstract] Proc Am Soc Clin Oncol 35:1237, 1999
33.
Zurück zum Zitat Picus J, Schultz M (1999) A phase II Trial of docetaxel in Patients with hormone refractory prostate cancer (HRPC): Long term results. [abstract] Proc Am Soc Oncol 35:1206 Picus J, Schultz M (1999) A phase II Trial of docetaxel in Patients with hormone refractory prostate cancer (HRPC): Long term results. [abstract] Proc Am Soc Oncol 35:1206
34.
Zurück zum Zitat Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26:14–18 Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26:14–18
35.
Zurück zum Zitat Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19–23 Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19–23
36.
Zurück zum Zitat Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8–15 Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8–15
37.
Zurück zum Zitat Beer TM, Pierce W, Lowe BA, Henner WD (2000) Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer (HRPC): ASCO, 2000 Beer TM, Pierce W, Lowe BA, Henner WD (2000) Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer (HRPC): ASCO, 2000
38.
Zurück zum Zitat Gravis G, Bladou F, Salem N, Viens P (2001) Efficacy, quality of life (QoL) and tolerance with weekly docetaxel in metastatic hormone refractory prostate cancer: ASCO, 2001 Gravis G, Bladou F, Salem N, Viens P (2001) Efficacy, quality of life (QoL) and tolerance with weekly docetaxel in metastatic hormone refractory prostate cancer: ASCO, 2001
39.
Zurück zum Zitat Benson R, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8:375 Benson R, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8:375
40.
Zurück zum Zitat Hartley- Asp B, Kruse E (1986) Nuclear protein matrix as a target for estramustine induced cell death. Prostate 9:387PubMed Hartley- Asp B, Kruse E (1986) Nuclear protein matrix as a target for estramustine induced cell death. Prostate 9:387PubMed
41.
Zurück zum Zitat Petrylak DP, MacArthur RB, O‘Connor J et al. (1999) Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol 17:958–967PubMed Petrylak DP, MacArthur RB, O‘Connor J et al. (1999) Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol 17:958–967PubMed
42.
Zurück zum Zitat Kreis W, Budman DR, Fetten J et al. (1999) Phase I trial of the combination of daily estramutine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38 Kreis W, Budman DR, Fetten J et al. (1999) Phase I trial of the combination of daily estramutine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38
43.
Zurück zum Zitat Natale RB, Zaretzky S (1998) Phase I/II study of estramustine (E) and taxotere (T) in patients with metastatic hormone refractory prostate cancer. (HRPC) [abstract]. Proc Am Soc Clin Oncol 17:384a Natale RB, Zaretzky S (1998) Phase I/II study of estramustine (E) and taxotere (T) in patients with metastatic hormone refractory prostate cancer. (HRPC) [abstract]. Proc Am Soc Clin Oncol 17:384a
44.
Zurück zum Zitat Miller K, Steiner U, Machtens S et al. (2003) Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone-refractory prostate cancer (HRPC): a multicenter phase II trial. Proc ASCO 22:1660 Miller K, Steiner U, Machtens S et al. (2003) Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone-refractory prostate cancer (HRPC): a multicenter phase II trial. Proc ASCO 22:1660
45.
Zurück zum Zitat Oudard S, Banu E, Voog E et al. (2003) Results of a phase II randomised trial of docetaxel, estramustine and prednisone—two schedules—versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. Eur Urol 2 [Suppl 1]:189 Oudard S, Banu E, Voog E et al. (2003) Results of a phase II randomised trial of docetaxel, estramustine and prednisone—two schedules—versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. Eur Urol 2 [Suppl 1]:189
46.
Zurück zum Zitat Heidenreich A, Carl S, Gleissner S, Moormann O (2003) Docetaxel and mitoxantrone in the management of hormone-refractory prostate cancer. Proc ASCO 22:1655 Heidenreich A, Carl S, Gleissner S, Moormann O (2003) Docetaxel and mitoxantrone in the management of hormone-refractory prostate cancer. Proc ASCO 22:1655
47.
Zurück zum Zitat Crawford ED, Pauler DK, Tangen CM et al. (2004) Three-month change of PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Date from Southwest Oncology Group Study 9916. Proc ASCO 23:382, #4505 Crawford ED, Pauler DK, Tangen CM et al. (2004) Three-month change of PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Date from Southwest Oncology Group Study 9916. Proc ASCO 23:382, #4505
Metadaten
Titel
Aktuelle Optionen der taxanbasierten Chemotherapie des hormonrefraktären Prostatakarzinoms
verfasst von
Prof. Dr. A. Heidenreich
J. Wolf
K. Miller
Publikationsdatum
01.01.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 1/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-004-0803-3

Weitere Artikel der Ausgabe 1/2005

Der Onkologe 1/2005 Zur Ausgabe

Weiterbildung · Zertifizierte Fortbildung

Lokal fortgeschrittenes Harnblasenkarzinom

Algorithmus + Klassifikation

Algorithmus zum Schilddrüsenkarzinom

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Schon länger ist bekannt, dass die Aktivität des Immunsystems mit den Jahreszeiten variiert. Auch die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen, wie eine Studie bei fortgeschrittenem nichtkleinzelligem Lungenkarzinom zeigt.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.